Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 4, 2012, Pages 558-570

  Teli, Mahesh Kumar ^a   Rajanikant, G K ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY CALICUT   (India)

Author keywords

3D QSAR; Inflammatory disorders; Pharmacophore; Quinoline 3 carbonitrile derivatives; TNF ; Tumour progression locus 2

Indexed keywords

PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINOLINE 3 CARBONITRILE DERIVATIVE; TUMOR PROGRESSION LOCUS 2; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION COEFFICIENT; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; FISHER EXACT TEST; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS;

DATABASES, FACTUAL; HUMANS; MAP KINASE KINASE KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864062864     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.603128     Document Type: Article

References (30)

1. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K et al. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem 2005;280:23748-23757.
2. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;103:1071-1083.
3. Eliopoulos AG, Dumitru CD, Wang CC, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. Embo J 2002;21:4831-4840.
4. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. Embo J 2003;22:3855-3864.
5. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-1574.
6. RodrÍguez C, Pozo M, Nieto E, Fernández M, Alemany S. TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal 2006;18:1376-1385.
7. Stafford MJ, Morrice NA, Peggie MW, Cohen P. Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett 2006; 580:4010-4014.
8. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A et al. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J Clin Invest 2004;114:857-866.
9. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
10. Aggarwal BB, Samanta A, Feldmann MA. Compendium of Cytokines and Other Mediators of Host Defense. Academic Press, San Diego 2001: Pp. 413-434.
11. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001;19: 163-196.
12. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor-alphaimplications for psoriasis. Exp Dermatol 2004;13:193-222.
13. Simmons DL. What makes a good anti-inflammatory drug target? Drug Discov Today 2006;11:210-219.
14. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-631.
15. Smyth A, Houlihan DD, Tuite H, Fleming C, O'Gorman TA. Necrotising fasciitis of the shoulder in association with rheumatoid arthritis treated with etanercept: A case report. J Med Case Reports 2010;4:367.
16. Gutierrez M, Becciolini A, Bertolazzi C, Di Geso L, Tardella M, Ariani A et al. [Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab]. Reumatismo 2010;62:221-224.
17. Shenoi S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: An evidence-based review. Paediatr Drugs 2010;12:367-377.
18. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, Li HQ et al. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3- carbonitriles for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett 2006;16:6067-6072.
19. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, Telliez JB et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 2007; 282:33295-33304.
20. Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S et al. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: Selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6- aminoquinoline-3-carbonitriles. J Med Chem 2007;50:4728-4745.
21. Caivano M, Rodriguez C, Cohen P, Alemany S. 15-Deoxy- Delta12,14-prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide. J Biol Chem 2003;278:52124-52130.
22. Gavrin LK, Green N, Hu Y, Janz K, Kaila N, Li HQ et al. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine- 3-carbonitriles: Synthesis and structure-activity relationships. Bioorg Med Chem Lett 2005;15:5288-5292.
23. Kaila N, Green N, Li HQ, Hu Y, Janz K, Gavrin LK et al. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7] naphthyridine-3-carbonitriles. Bioorg Med Chem 2007;15:6425-6442.
24. Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A et al. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett 2009;19:3485-3488.
25. Mahipal, Tanwar OP, Karthikeyan C, Moorthy NS, Trivedi P. 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors. Med Chem 2010;6:287-285.
26. Samantha L, Cesare M, Aleksey K, Mattia S, Stefano M, Elena C, Dorotea R, Alessandro C. SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg Med Chem Lett 2008;16:5695-5703.
27. User manual Phase, version 3.0, Schrödinger, LLC, New York, NY, 2008.
28. Shah UA, Deokar HS, Kadam SS, Kulkarni VM. Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4- methylsulfonylphenyl)pyrimidines as COX-2 inhibitors. Mol Divers 2010;14:559-568.
29. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647-671.
30. Eng J. Receiver operating characteristic analysis: A primer. Acad Radiol 2005;12:909-916.